---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-019761"
form_type: "8-K"
ticker: "BBIO"
cik: "0001743881"
company_name: "BridgeBio Pharma, Inc."
filed_at: "2026-05-08T23:59:59+00:00"
generated_at: "2026-05-14T21:08:58.389446+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BridgeBio Pharma establishes $500M at-the-market equity offering program

## Summary
- Up to $500M in common stock may be sold via ATM through Goldman Sachs and Leerink Partners.
- Sales agents will receive up to 3.0% commission on gross proceeds; company not obligated to sell.
- Prior May 2023 equity distribution agreement terminated in conjunction with new facility.
- Registration statement on Form S-3ASR filed to support the offering.

## SEC filing metadata
- accession: 0001140361-26-019761
- form_type: 8-K
- ticker: BBIO
- cik: 0001743881
- company_name: BridgeBio Pharma, Inc.
- filed_at: 2026-05-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 1.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1743881/000114036126019761/0001140361-26-019761-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1743881/000114036126019761/ny20072667x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-019761
- JSON: https://secwatch.observer/filing/0001140361-26-019761.json
- Plain text: https://secwatch.observer/filing/0001140361-26-019761.txt

## Source-grounded claims
- claim_id: 3dd680ec5117a6e6daad7636858fe14cab516cc8
  claim: BridgeBio Pharma, Inc. terminated Equity Distribution Agreement, dated May 4, 2023 with Goldman Sachs & Co. LLC and Leerink Partners LLC (formerly known as SVB Securities LLC) (effective 2026-05-07).
  evidence_excerpt: On May 7, 2026, in connection with entering into the Agreement, the Company agreed with Goldman Sachs and Leerink Partners (formerly known as SVB Securities LLC), to terminate that certain Equity Distribution Agreement, dated May 4, 2023, by and among the Company, Goldman Sachs and Leerink Partners, effective as of May 7, 2026.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036126019761/0001140361-26-019761-index.htm
- claim_id: 96143f4e4c837e7f1fdbcb3dee124afa4eaa9d8e
  claim: BridgeBio Pharma, Inc. entered into Equity Distribution Agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC valued at $500,000,000 (effective 2026-05-07).
  evidence_excerpt: On May 7, 2026, the Company entered into an Equity Distribution Agreement (the “Agreement”) with Goldman Sachs & Co. LLC (“Goldman Sachs”) and Leerink Partners LLC (“Leerink Partners”, and together with Goldman Sachs, the “Sales Agents”) with respect to an “at-the-market” offering program under which the Company may issue and sell, from time to time at its sole discretion and pursuant to a prospectus supplement, shares of its common stock, par value $0.001 per share (“Common Stock”), having an aggregate offering price of up to $500,000,000 (the “Placement Shares”), through the Sales Agents.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1743881/000114036126019761/0001140361-26-019761-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.